Get started
Author

Anna Elgart

Observed name: A. Elgart
OpenAlex ID: A5049144787
Improved Oral Bioavailability of BCS Class 2 Compounds by Self Nano-Emulsifying Drug Delivery Systems (SNEDDS): The Underlying Mechanisms for Amiodarone and Talinolol
2013 · Anna Elgart, Irina Cherniakov, et al. · Pharmaceutical Research · 106
Lipospheres and pro-nano lipospheres for delivery of poorly water soluble compounds
2012 · Anna Elgart, Irina Cherniakov, et al. · Chemistry and Physics of Lipids · 95
Novel d -Xylose Derivatives Stimulate Muscle Glucose Uptake by Activating AMP-Activated Protein Kinase α
2008 · Arie Gruzman, Ofer Shamni, et al. · Journal of Medicinal Chemistry · 33
Cyclosporin pro-dispersion liposphere formulation
2011 · Avi Avramoff, Wahid Khan, et al. · Journal of Controlled Release · 28
Polysaccharide Pharmacokinetics: Amphotericin B Arabinogalactan Conjugate—A Drug Delivery System or a New Pharmaceutical Entity?
2010 · Anna Elgart, Shimon Farber, et al. · Biomacromolecules · 26
Population Pharmacokinetic Modeling and Simulation of TV‐46000: A Long‐Acting Injectable Formulation of Risperidone
2022 · Itay Perlstein, Avia Merenlender Wagner, et al. · Clinical Pharmacology in Drug Development · 18
PDF
A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial
2024 · John M. Kane, Roy Eshet, et al. · CNS Drugs · 14
Pharmacokinetics and safety of single and multiple doses of rasagiline in healthy Japanese and caucasian subjects
2018 · Anna Elgart, Laura Rabinovich‐Guilatt, et al. · Basic & Clinical Pharmacology & Toxicology · 11
A population pharmacokinetic meta‐analysis of custirsen, an antisense oligonucleotide, in oncology patients and healthy subjects
2017 · Alena Y. Edwards, Anna Elgart, et al. · British Journal of Clinical Pharmacology · 11
PDF
The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women
2018 · Anna Elgart, Arik A. Zur, et al. · European Journal of Clinical Pharmacology · 9
Population Pharmacokinetic Modeling of TV-46000, a Risperidone Long-Acting Subcutaneous Antipsychotic for the Treatment of Patients with Schizophrenia
2025 · Itay Perlstein, Avia Merenlender Wagner, et al. · Neurology and Therapy · 8
Impact of dosing regimen of custirsen, an antisense oligonucleotide, on safety, tolerability and cardiac repolarization in healthy subjects
2015 · Laura Rabinovich‐Guilatt, Anna Elgart, et al. · British Journal of Clinical Pharmacology · 8
PDF
Antihyperglycaemic activity of 2,4:3,5‐dibenzylidene‐D‐xylose‐diethyl dithioacetal in diabetic mice
2011 · Arie Gruzman, Anna Elgart, et al. · Journal of Cellular and Molecular Medicine · 8
PDF
A Thorough QT/QTc Study With Laquinimod, a Novel Immunomodulator in Development for Multiple Sclerosis and Huntington Disease
2018 · Ofer Spiegelstein, Dorit Mimrod, et al. · Clinical Pharmacology in Drug Development · 7
PDF
Safety, Tolerability, and Pharmacokinetics of Subcutaneous Extended-Release Injectable Olanzapine in Patients with Schizophrenia and Schizoaffective Disorder
2026 · Irina Cherniakov, Avia Merenlender Wagner, et al. · Clinical Drug Investigation · 4
PDF
TV-46000, A Long-Acting Subcutaneous Antipsychotic Agent, Demonstrated Improved Patient-Centered Outcomes in Patients with Schizophrenia
2024 · Leslie Citrome, Mark Suett, et al. · Neuropsychiatric Disease and Treatment · 4
PDF
The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator
2020 · Anna Elgart, David J. Greenblatt, et al. · Clinical Pharmacology in Drug Development · 3
The SOLARIS protocol: a phase 3, randomized, double-blind, placebo-controlled trial assessing safety and efficacy of TV-44749 in adults with schizophrenia
2023 · C.U. Correll, A. Ahn, et al. · Neuroscience Applied · 2
Evaluation of the pharmacokinetics of TV-44749, newly developed once-monthly extended-release formulation of olanzapine in healthy volunteers and patients with schizophrenia
2023 · I. Cherniakov, A. Merenlender Wagner, et al. · Neuroscience Applied · 2
P.0463 Phase 1 open-label study assessing the pharmacokinetics and safety of TV-46000, a novel long-acting subcutaneous injectable formulation of risperidone
2021 · A. Merenlender Wagner, A. Elgart, et al. · European Neuropsychopharmacology · 2
Population pharmacokinetic model- and simulation-based dose selection for a phase 3 trial of subcutaneous long-acting olanzapine in adults with schizophrenia
2024 · I. Perlstein, R. Gomeni, et al. · Neuroscience Applied · 1
P.0461 Population pharmacokinetic modeling and simulation to guide dose selection for TV-46000, a new long-acting formulation of risperidone for subcutaneous injection
2021 · I. Perlstein, A. Merenlender Wagner, et al. · European Neuropsychopharmacology · 1
Characterization of local tolerability of TV-46000, a long-acting subcutaneous formulation of risperidone for the treatment of schizophrenia
2026 · Christoph U. Correll, John M. Kane, et al. · Journal of Psychiatric Research
A Phase 1 Open-Label Study Assessing the Safety and Pharmacokinetics of TV-46000, an Extended-Release Injectable Suspension of Risperidone for Subcutaneous Use
2026 · Avia Merenlender Wagner, Itay Perlstein, et al. · CNS Drugs
PDF
An open-label trial to compare exposures of subcutaneous long-acting injectable use olanzapine (TV-44749) versus oral olanzapine in adults with schizophrenia (ORBIT)
2026 · A. Merenlender Wagner, K. Shulman, et al. · European Psychiatry
PDF
Works count: 32
Citation count: 401
H-index: 9
I10-index: 9
Year
Topic
Type